BI 6727 and gemcitabine combination therapy in pancreatic cancer

OP Jones
Introduction: Though adjuvant chemotherapy improves survival following surgery, pancreatic cancer carries a poor prognosis. Alternatives are required to the current drug regimens consisting of S-phase dependent drugs such as gemcitabine. PLK1 is a passenger protein involved in G2/M phases which presents a novel target to inhibit in combination with current therapies, which may help overcome inate and acquired resistance. Aim: To evaluate the potential role of a novel PLK1 inhibitor, BI 6727 in pancreatic cancer...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.